Medicare Rx Sponsors, States May Partner For Enhanced Drug Pricing Power
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicaid programs and Medicare prescription drug plans will both be exempt from "best price" restrictions, providing an opportunity to negotiate drug prices together, Maine legislator says.
You may also be interested in...
Medicare Rx Plan Negotiations Will Avert Drug Industry "Windfall" – PhRMA
The industry group disputes predictions that the 2006 transfer of "dual eligibles" to Medicare will significantly benefit drug makers as Medicaid "best price" requirements no longer apply. However, states may lose price negotiating power, PhRMA says.
Medicare Rx Plan Negotiations Will Avert Drug Industry "Windfall" – PhRMA
The industry group disputes predictions that the 2006 transfer of "dual eligibles" to Medicare will significantly benefit drug makers as Medicaid "best price" requirements no longer apply. However, states may lose price negotiating power, PhRMA says.
Medicaid Cost-Containment Strategies May Include PDL For Antipsychotics
Increased flexibility in controlling drug costs will be required for states to maintain their bargaining power following the shift of “dual eligibles” to Medicare in 2006, Oklahoma Medicaid director says.